Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Karyopharm Therapeutics (KPTI) Long-Term Debt Issuances (2024 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Long-Term Debt Issuances for 4 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Issuances rose 114.71% year-over-year to $12.2 million, compared with a TTM value of -$71.0 million through Dec 2025, up 14.71%, and an annual FY2025 reading of $12.2 million, changed N/A over the prior year.
  • Long-Term Debt Issuances was $12.2 million for Q4 2025 at Karyopharm Therapeutics, up from -$83.3 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $12.2 million in Q4 2025 and bottomed at -$83.3 million in Q4 2024.